Read This Before Buying M1 Kliniken AG (ETR:M12) For Its Dividend

Dividend paying stocks like M1 Kliniken AG (ETR:M12) tend to be popular with investors, and for good reason - some research suggests a significant amount of all stock market returns come from reinvested dividends. If you are hoping to live on your dividends, it's important to be more stringent with your investments than the average punter. Regular readers know we like to apply the same approach to each dividend stock, and we hope you'll find our analysis useful.

In this case, M1 Kliniken likely looks attractive to dividend investors, given its 3.4% dividend yield and four-year payment history. We'd agree the yield does look enticing. Some simple analysis can reduce the risk of holding M1 Kliniken for its dividend, and we'll focus on the most important aspects below.

Click the interactive chart for our full dividend analysis

historic-dividend
XTRA:M12 Historic Dividend September 7th 2020
Advertisement

Payout ratios

Dividends are typically paid from company earnings. If a company pays more in dividends than it earned, then the dividend might become unsustainable - hardly an ideal situation. Comparing dividend payments to a company's net profit after tax is a simple way of reality-checking whether a dividend is sustainable. M1 Kliniken paid out 67% of its profit as dividends, over the trailing twelve month period. A payout ratio above 50% generally implies a business is reaching maturity, although it is still possible to reinvest in the business or increase the dividend over time.

Another important check we do is to see if the free cash flow generated is sufficient to pay the dividend. Unfortunately, while M1 Kliniken pays a dividend, it also reported negative free cash flow last year. While there may be a good reason for this, it's not ideal from a dividend perspective.

With a strong net cash balance, M1 Kliniken investors may not have much to worry about in the near term from a dividend perspective.

Consider getting our latest analysis on M1 Kliniken's financial position here.

Dividend Volatility

From the perspective of an income investor who wants to earn dividends for many years, there is not much point buying a stock if its dividend is regularly cut or is not reliable. Looking at the data, we can see that M1 Kliniken has been paying a dividend for the past four years. The dividend has not fluctuated much, but with a relatively short payment history, we can't be sure this is sustainable across a full market cycle. Its most recent annual dividend was €0.3 per share, effectively flat on its first payment four years ago.

It's good to see at least some dividend growth. Yet with a relatively short dividend paying history, we wouldn't want to depend on this dividend too heavily.

Dividend Growth Potential

While dividend payments have been relatively reliable, it would also be nice if earnings per share (EPS) were growing, as this is essential to maintaining the dividend's purchasing power over the long term. M1 Kliniken has grown its earnings per share at 8.0% per annum over the past five years. The rate at which earnings have grown is quite decent, and by paying out more than half of its earnings as dividends, the company is striking a reasonable balance between reinvestment and returns to shareholders.

We'd also point out that M1 Kliniken issued a meaningful number of new shares in the past year. Regularly issuing new shares can be detrimental - it's hard to grow dividends per share when new shares are regularly being created.

Conclusion

To summarise, shareholders should always check that M1 Kliniken's dividends are affordable, that its dividend payments are relatively stable, and that it has decent prospects for growing its earnings and dividend. M1 Kliniken gets a pass on its dividend payout ratio, but it paid out virtually all of its cash flow as dividends. This may just be a one-off, but we'd keep an eye on this. Unfortunately, earnings growth has also been mediocre, and we think it has not been paying dividends long enough to demonstrate resilience across economic cycles. Overall, M1 Kliniken falls short in several key areas here. Unless the investor has strong grounds for an alternative conclusion, we find it hard to get interested in a dividend stock with these characteristics.

Companies possessing a stable dividend policy will likely enjoy greater investor interest than those suffering from a more inconsistent approach. Meanwhile, despite the importance of dividend payments, they are not the only factors our readers should know when assessing a company. Just as an example, we've come accross 4 warning signs for M1 Kliniken you should be aware of, and 1 of them is a bit concerning.

We have also put together a list of global stocks with a market capitalisation above $1bn and yielding more 3%.

If you’re looking to trade M1 Kliniken, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. Their clients from over 200 countries and territories trade stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted


New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020


Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.

M
mitchell_lawler
mitchell_lawler

Everyone's watching the oil price. The harder problem is the gas that can't take a detour.

Everyone's watching the oil price. The harder problem is the gas that can't take a detour. cover
98
R
Rob_Curious

What I've learnt in the last six months is that fuel supply disruption is a real portfolio risk, and one of the better hedges is a small allocation to shipping. Though it's insane how much these have run up this year.

f
frank_ub3n0

Spot on. Shipping and logistics is much larger constraint for gas than oil. Sorry to break it to you. No quick fixes for that.

Mitchell Lawler

What happens to energy stocks as the fix gets built?

What happens to energy stocks as the fix gets built? cover
Conflict around the Strait of Hormuz has led investors to oil and tankers. The trouble is, the antidote to the chokepoints is already being built, and it may not reward the same energy stocks.
22

About XTRA:M12

M1 Kliniken

Provides aesthetic medicine and plastic surgery services in Germany, Austria, the Netherlands, Switzerland, Croatia, Hungary, Bulgaria, and Romania.

Flawless balance sheet average dividend payer.

Advertisement

Weekly Picks

CE
Ceazar
SPAI logo
Ceazar on Sparc AI ·

When GPS fails: this small cap is fixing a $54B drone problem

Fair Value:CA$5.2532.6% undervalued
205 users have followed this narrative
0 users have commented on this narrative
31 users have liked this narrative
CO
composite32
Emerging Author
AROC logo
composite32 on Archrock ·

AI Needs Power. Power Needs Gas. Gas Needs Compression: The Archrock Investment Thesis

Fair Value:US$44.8829.7% undervalued
32 users have followed this narrative
2 users have commented on this narrative
3 users have liked this narrative
JO
John_Eric
Emerging Author
AEIS logo
John_Eric on Advanced Energy Industries ·

AEIS Is Firing on Every Cylinder. My Problem Is the Safety Factor.

Fair Value:US$567.8653.8% undervalued
19 users have followed this narrative
0 users have commented on this narrative
7 users have liked this narrative
IS
LRCX logo
isidrohg on Lam Research ·

The Memory Shortage Is Lam's Order Book — Whether It Persists Or Resolves

Fair Value:US$423.8532.0% undervalued
23 users have followed this narrative
0 users have commented on this narrative
7 users have liked this narrative

Updated Narratives

JO
John_Eric
PL logo
John_Eric on Planet Labs PBC ·

I Went Looking for a Crashed Space Stock.I Found a Machine That Remembers Earth.

Fair Value:US$3147.0% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AN
andrei9868
APP logo
andrei9868 on AppLovin ·

Axon Is Still Compounding — the Market Is Pricing a Broken Growth Story

Fair Value:US$46233.3% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AN
andrei9868
FSLR logo
andrei9868 on First Solar ·

The Market Is Pricing Policy Noise — Not 45 GW of Contracted U.S. Modules

Fair Value:US$26325.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$302.8326.6% undervalued
1477 users have followed this narrative
8 users have commented on this narrative
35 users have liked this narrative
AN
AnalystConsensusTarget
GOOGL logo
AnalystConsensusTarget on Alphabet ·

GOOGL: AI Platform Expansion And Cloud Demand Will Support Durable Performance Amid Competitive Pressures

Fair Value:US$427.8918.3% undervalued
1644 users have followed this narrative
0 users have commented on this narrative
19 users have liked this narrative
AN
AnalystConsensusTarget
AMZN logo
AnalystConsensusTarget on Amazon.com ·

AMZN: Acceleration In Cloud And AI Will Drive Margin Expansion Ahead

Fair Value:US$32722.4% undervalued
1658 users have followed this narrative
1 users have commented on this narrative
16 users have liked this narrative

Trending Discussion

AN
TPG0 logo
anthony_x0j2w on Platform Group SE KGaA ·

Hello,(I am a shareholder).I spent the summer investigating in whatever I was able to find in the press, the trustee, or legal, and comparing it to FS Benner's declaration/transcripts:press: MM has a tendancy to use facts, modify them and turn them the way they want: 100% of their claims against TPG0 is traçable factually, 80% is flawed and interpreted. Example are numerous: 11M loans banks to be paid seems right, but it has not been an issue at all, it has been paid in full. (and it happens all the time in every business...); the previous HR becoming a financial director in the article herself being attacked by TPG on the legal side; the wrong address of curator (if truly announced by TPG).Trustee: according to my research (which can be incomplete) no communication to the Nordic trustee (hereby, bond holders) has been done on a, indebtedness (late payment) > 1M€, which is their obligation by contract (clause 14.d - https://corporate.the-platform-group.com/bond/) => this is a sign of a huge lie and fraud, or the sign that there is no indebtedness > 1M€ over the whole TPG group.Legal: still awaiting for an answer, probable that I won't get it.VALUATIONYou can spent hours working the fundamentals, if they're flawed...the thesis falls.Anyway, I always substracts the badwill (that I consider non-current - you have it in the CFS) & non-controlling interests from my valuation:Earnings ~22MFCF ~40M€The financial statements are not the issue here, we are more on an cheap option on the sincerity of the accounts that a real valuation. Unfortunately, these are unverifiable elements, hence the low price./!\ Careful:the accounts are consolidated and skip the subsidiaries issues...Careful with the business model: TPG0 is a financial holding that acquire subsidiaries, hold the debt, and has no operations. 100% of the Cash Flow comes from subs' dividends => it is a risk here, more a plumber risk than an operational one, but nevertheless...The auditor is too small, and managed by the same firm than before, with 140K€/year commission => it's too low, nobody external really reviewed what Benner and his team are doing internallycapital increase do not go through the CFS, but through change in equity AND equity in the BSIf the equity stays low too long, the WACC increase will be unbearable (I have a 30% global, with a 118% on equity): diluting is expensive => TPG machine can stay broken for a while.Most of the people I talk with never saw this, while this is ESSENTIAL to Benner's business model.SEVERAL EVENTS THAT COULD CHANGE:AEP is being audited by KPMG: if Benner plays the "we will propose KPMG to our shareholders BEOY", this can increase the trust in him significantly/KPMG (or other) to validate the 2026 IFRS accounts & having a word on HGB's: though still consolidated, at least we'll know...AEP being eventually acquired: while it carries a high integration risk due to its size, they talked about it so many times, that trust goes with it.Without this combination of event, the equity is doomed to stay at this level, IMO.Do not forget to also follow the bond: with TPG's announced safe harbor plan for buyback (25% of daily exchange), it is also interesting to check this illiquid and retail market: https://live.deutsche-boerse.com/bond/no0013256834-the-platform-group-ag-8-875-24-28?mic=XFRA

1
|
0